Recent Updates
Recently added Catalysts

TBS-2025

Phase 1/2

Acute Myeloid Leukemia | Biologics | Oncology |TuHURA Biosciences, Inc.|Trials Updated: Nov 16, 2026

TBS-2025 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Nov 2026

TBS-2025 target and mechanism

Molecular targetVISTA
Target classProtein
ModalityBiologics

Also known as trovostobart

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment55

FDA Designations

No designations recorded

TBS-2025 clinical trials

TBS-2025 · 1 trial · 1 indication

Phase 1/2 1
NCT07939971A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AMLAcute Myeloid Leukemia
NOT YET_RECRUITING55 Analytics
PHASE1/PHASE2NOT YET_RECRUITING
A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML
Acute Myeloid LeukemiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with dose limiting toxicities (DLTs)
At the end of Cycle 1 ( each cycle is 28 days)
Number of participants with an AE
Baseline through study completion, an average of 2 years

Secondary Endpoints

Pharmacokinetic (PK) Serum Concentration of TBS-2025
Baseline through the start of Cycle 4 (each cycle is 28 days)
Number of participants with anti-TBS-2025 antibody formation
Baseline through the end of Cycle 4 (each cycle is 28 days)
Rate of Complete Remission
Baseline to study completion, an average of 2 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Dose EscalationEXPERIMENTALTBS-2025 administered at multiple, escalating dose levels as monotherapy
Dose OptimizationEXPERIMENTALTBS-2025 administered at 2 or more dose levels as monotherapy

Interventions

NameTypeDescription
TBS-2025BIOLOGICALTBS-2025 is a fully human IgG1-kappa monoclonal antibody that binds specifically to the hVISTA-ECD and blocks interaction with endogenous VISTA ligands.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Documented r/r AML (BM blasts ≥5%) with NPM1-mutation * Received, and has progressed, recurred, or is intolerant of approved/effective therapeutic options, including treatment with a menin inhibitor, for r/r AML, or declines treatment with these therapies. Relapsed disease is ...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 16, 2026NCT07939971New Trial Detected: Not Yet Recruiting